A Newer Kind of Gene Editing Promises to Edit ‘Nurture’ Over ‘Nature’

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-08T09:15:25.813Z • Permanent link

Scientists at the Broad Institute of MIT and Harvard, led by Professor George Church, have made a groundbreaking discovery in the field of gene editing. Their new approach, called epigenome editing, aims to treat the molecular scars we collect throughout our lives. The team has been working on this project for several years, using a novel technique to modify the epigenetic marks on our DNA. These marks are crucial in regulating gene expression, but they can also be damaged by environmental factors, leading to various diseases.

The breakthrough was announced in a paper published in Nature, where the researchers presented their results. The team used a new enzyme, called CRISPR-Cas13, to target and remove these epigenetic marks. They tested their approach on mouse models of human diseases, such as cancer and neurodegenerative disorders. The results were promising, with significant improvements in disease symptoms and outcomes. This technology has the potential to revolutionize the way we approach genetic diseases, which have long been a major challenge in the field of medicine.

The Broad Institute is a leading institution in the field of genomics and gene editing. Founded by President Obama in 2010, it brings together researchers from Harvard and MIT to tackle some of the world's most pressing scientific challenges. The institute has made significant contributions to our understanding of the human genome and has developed several groundbreaking technologies, including CRISPR-Cas9, the most widely used gene editing tool today.

The implications of this discovery are significant for the scientific community, particularly for researchers working on genetic diseases. Epigenome editing has the potential to treat a wide range of diseases, from cancer to neurodegenerative disorders. This approach could also be used to develop new therapies for genetic diseases, which have long been a major challenge in the field of medicine. Companies such as Editas Medicine and CRISPR Therapeutics are already working on developing epigenome editing technologies, and this breakthrough could give them a significant advantage in the market.

The impact of epigenome editing on the research community will also be significant. Researchers will have access to a new tool that can be used to study the molecular mechanisms of disease and develop new therapies. This could lead to a major shift in the way we approach genetic diseases, with a focus on treating the molecular scars that we collect throughout our lives. The Broad Institute is already working with researchers from around the world to develop this technology, and it is likely that we will see significant advancements in the field in the coming years.

Epigenome editing is not a new concept, but it has been largely overlooked in recent years. This is because traditional gene editing techniques, such as CRISPR-Cas9, have been able to achieve similar results with greater ease and efficiency. However, traditional gene editing techniques often involve rewriting the underlying DNA sequence, which can be difficult and error-prone. Epigenome editing, on the other hand, targets the epigenetic marks that regulate gene expression, which are often more accessible and easier to modify.